Back to results
US 8,962,236 B2Granted
Epigenetic biomarker ADAMTS9 for diagnosis and prognosis of gastric cancer
AssigneeThe Chinese University of Hong Kong
InventorsJun Yu, Joseph Jao Yiu Sung
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the ADAMTS9 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing ADAMTS9 gene expression or activity.
Claims7
A method for assessing risk of cancer-related death among gastric cancer patients, comprising the steps of:
- (a) treating gastric tissue samples taken from the patients with a bisulfite;
- (b) performing a methylation-specific polymerase chain reaction to amplify a genomic sequence comprising SEQ ID NO:1 using an oligonucleotide primer consisting of the nucleotide sequence of SEQ ID NO:
- 10, 11, 12, 13, 14 or 15, and determining whether in each sample genomic sequence of SEQ ID NO:1 is methylated or unmethylated;
- and
- (c) assigning a higher risk of cancer-related death to a patient whose sample contains methylated genomic sequence of SEQ ID NO:1 and assigning a lower risk of cancer-related death to another patient whose sample contains unmethylated genomic sequence of SEQ ID NO:1.
2 more elements
Dependencies are inferred from the claim text.